MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

MDS Virtual Congress 2020

September 12-16, 2020. Virtual Congress. www.mdscongress.org

View by Title View Categories
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Detecting Lower Extremity Ataxia: Toe-Heel Tap is the Best Screening Tool

    E. Smith, D. Whitney, D. Bhatti, A. Hellman, D.J Bertoni, D. Torres-Russotto (Omaha, NE, USA)

  • Detection of alpha-synuclein aggregation from submandibular and esophageal tissue of patients with synucleinopathies

    T. Yamasaki, T. Sudhakar, E. Ostrakhovitch, E. Song (Lexington, KY, USA)

  • Detection of Cognitive Changes in Premanifest Huntington’s disease Using the Repeatable Battery for the Assessment of Neuropsychological Status

    A. Mustafa, J. Corey-Bloom, H. Smith, J. Castleton, P. Gilbert (San Diego, CA, USA)

  • Determinants of quality of life in a large, online cohort of patients with Parkinson’s disease

    M. Bock, E. Brown, C. Tanner (San Francisco, CA, USA)

  • Determination of freezing of gait with wearable sensors in patients with Parkinson’s disease

    U. Eliiyi, P. Keskinoglu, T. Kahraman, A. Özkurt, B. Yürdem, G. Duran, B. Dönmez Colakoglu, A. Genc (Izmir, Turkey)

  • Determination of non-motor symptoms in Parkinson’s disease in Kazakhstan (on the example of the city of Almaty)

    A. Aralbayeva, A. Kondybaeva, S. Kamenova, K. Kuzhibaeva (Almaty, Kazakhstan)

  • Deutetrabenazine for Huntington’s disease chorea—A Single Center’s Experience

    D. Fischer, R. Caskey, M. Dean, V. Sung (Birmingham, AL, USA)

  • Deutetrabenazine Reduces Involuntary Movements in Patients Most Severely Impacted by Tardive Dyskinesia in a 3-year Open-Label Extension Trial

    J. Bona, H. Barkay, A. Wilhelm, N. Chaijale, M. Gordon (Atlanta, GA, USA)

  • Developing A Novel Disease-Specific Psychosis Severity Scale in Parkinson’s disease (Psy-PD): A Pilot Study

    Y.M Wan, E.K Tan, D. Aarsland, T.S Lee, Y.L Lo, SKS. Ting, P. Martinez-Martin, K.R Chaudhuri (London, United Kingdom)

  • Development and Characterization of an Ultrasensitive Assay Platform for Detection of PD Associated alpha-Synuclein Oligomers in Human Blood

    D. Robakis, A. Chiu, B. Chang, R. Rubenstein (Brooklyn, NY, USA)

  • « Previous Page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • …
  • 149
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley